Human Rights Council Decision 2/107. Access to medication in the context of pandemics such as HIV/AIDS, tuberculosis and malaria The Human Rights Council decides to adopt the following text: “The Human Rights Council recalls all the resolutions concerning access to medication in the context of pandemics such as HIV/AIDS, tuberculosis and malaria that were adopted by the Commission on Human Rights; “Considers paragraph 6 of General Assembly resolution 60/251 of 15 March 2006 establishing the Human Rights Council; “Notes the report of the World Health Organization Commission on Intellectual Property Rights Innovation and Public Health; “Also notes the World Health Assembly resolution 59.24 of 27 May 2006 establishing the Intergovernmental Working Group on Public Health, Innovation, Essential Health Research and Intellectual Property Rights; “Requests the Secretary-General to continue to solicit comments from Governments, United Nations organs, programmes and specialized agencies and international and non-governmental organizations on the steps they have taken to improve access to medication in the context of pandemics such as HIV/AIDS, tuberculosis and malaria and to submit a report thereon to the Council at any session after its fourth session; “Requests the Secretary-General, when submitting his report to the Human Rights Council at any session after its fourth session, based on consultations with Governments, United Nations organs, programmes, specialized agencies, intergovernmental and non-governmental organizations and private sector, to include a study on the exploration of new and innovative financing mechanisms, bearing in mind the existing ones, which can help to improve the access to medication that fight those pandemics, from the perspective of human rights; “Also requests the Secretary-General, when submitting his report to the Human Rights Council at any session after its fourth session, taking into consideration the discussions carried out in the WHO Intergovernmental Working Group on Public Health, Innovation, Essential Health Research and Intellectual Property Rights and in consultations with Governments, United Nations organs, programmes, specialized agencies, intergovernmental and non-governmental organizations and private sector, to include an assessment of the impacts of intellectual property rights on access to medication in the